Ibogaine in Oklahoma

What the Breakthrough Therapy Act does

House Bill 3834 passed the Oklahoma House on 11 March 2026 by 68 to 23 and the Senate on 29 April by 33 to 9, according to its bill history. The House agreed the Senate’s amendments on 6 May, and Governor Kevin Stitt signed it on 12 May 2026. It takes effect on 1 November 2026.

It does not merely permit. The State Department of Health shall, subject to the availability of funds, contract with a drug developer to support multistate drug development clinical trials aimed at FDA approval of ibogaine-based therapies. That is a mandate with a funding condition attached, which is a more interesting instrument than a permission and a weaker one than an appropriation. And the condition is not academic: HB 3834 appropriates nothing. The revolving fund it creates is seeded only by intellectual-property proceeds, later appropriations, gifts and grants. A match requirement, a revenue share and a fund, all scaled to a state contribution of zero.

The Act takes its name from one of its own conditions: the developer must plan to file an investigational new drug application if it has not already, and to seek breakthrough therapy designation from the FDA under 21 U.S.C. 356.

The structure is a contract rather than a grant or an appropriation to a university. That distinction shapes everything else about the law: a contract can carry obligations, and Oklahoma used that.

What Oklahoma requires of a drug developer

A drug developer contracting with Oklahoma must:

• match the state’s investment in the trials;
• run the trials in Oklahoma, using local resources where possible;
• report quarterly on progress and on finances;
• and establish plans for accessible treatment after FDA approval, including priority access for state residents, an effort to secure third-party payor approval, means of access for uninsured and low-income patients, and the training and credentialing of Oklahoma medical providers to administer it.

Oklahoma also takes a stake in whatever the research produces. A contracting developer must plan to recognise the state’s economic interest in the intellectual property the trials generate, as a share of the proceeds proportional to Oklahoma’s contribution to the total cost, and remit that share to the health department, which deposits it in a new Ibogaine Development Revolving Fund. That fund is continuing rather than annual, and may be spent only on programmes or research benefiting at-risk Oklahomans with conditions treatable with ibogaine.

Kentucky enacted a materially identical mechanism a month earlier, on 14 April 2026. Set the enrolled Oklahoma text and the enacted Kentucky text side by side:

Eleven obligations, in the same order, in the same terms, twenty-eight days apart. That is not similarity. It is a common template, and the interesting question is who wrote it.

Section 6 shields Oklahoma physicians from professional discipline solely for recommending that a patient enrol in an ibogaine trial. We have read the other eight state instruments and found no equivalent provision in any of them.

Whether the clause survives contact with a real contract negotiation is another matter. A promise to seek insurance coverage is weaker than a price cap, and “priority access for state residents” will mean whatever the contract says it means. But it is the first attempt by a legislature to answer the question the others have left open, and it is worth watching for that reason alone.

What HB 3834 does not do

Oklahoma cannot reschedule a federally controlled substance. Possession remains an offence, no physician may prescribe ibogaine, and no provider may administer it outside an approved research protocol.

The mandate is conditional in practice. It directs the department to contract, subject to funds it does not provide, and it cannot make a developer sign on those terms. Texas found in March 2026 that no company’s proposal met its standard, and Oklahoma’s conditions are heavier than the ones Texas set, with no money behind them.

Oklahoma in context

Oklahoma’s distinguishing feature is the contractual form: a state buying a trial under terms, rather than granting money for one. It is one of nine states to have legislated on ibogaine since 2025, and one of six to have attached no money.

Mississippi, Kentucky and Oklahoma all require their programmes to work with another state that has taken the same step, which marks a shift from isolated state programmes towards a coordinated multistate effort. And four of the nine have claimed a share of the result: Texas not less than 20 per cent of intellectual-property revenue, Mississippi at least 20 per cent to its general fund, Kentucky and Oklahoma a share proportional to what they contributed. Four states have written themselves into the upside of a drug none of them has yet paid for. The federal position sets out the limit on what any of them can achieve.